Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Muscular Dystrophy - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 23 Nov 17

The "Muscular Dystrophy - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 2, 1, 27 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Muscular Dystrophy - Overview
  3. Muscular Dystrophy - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Muscular Dystrophy - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Muscular Dystrophy - Companies Involved in Therapeutics Development
  • Acceleron Pharma Inc
  • Achelios Therapeutics Inc
  • AMO Pharma Ltd
  • aTyr Pharma Inc
  • Benitec Biopharma Ltd
  • Bio Blast Pharma Ltd
  • Biophytis SAS
  • Corcept Therapeutics Inc
  • Evotec AG
  • Fulcrum Therapeutics Inc
  • Genethon SA
  • Ionis Pharmaceuticals Inc
  • Marina Biotech Inc
  • Medestea Research & Production SpA
  • Novogen Ltd
  • Pfizer Inc
  • Prothelia Inc
  • Recursion Pharmaceuticals Inc
  • SanBio Inc
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics Inc
  • Strykagen Corp
  • Takeda Pharmaceutical Co Ltd
  • Ultragenyx Pharmaceutical Inc
  • WAVE Life Sciences Ltd

For more information about this report visit https://www.researchandmarkets.com/research/8wpxjp/muscular

View source version on businesswire.com: http://www.businesswire.com/news/home/20171123005198/en/

Business Wire
www.businesswire.com

Last updated on: 23/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.